Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 316

Sort by

Sort Order Select

Journal Articles

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Bhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Jr, Fenghuang Zhan, Eric Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2024-206497

Published: 2024

Journal Articles

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Yihao Zhan, Hongling Peng, David E. Mery, Eric Siegel, Clyde Bailey, Catherine Ma, Hongwei Xu, Daisy V. Alapat, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1904.

https://doi.org/10.1182/blood-2024-203848

Published: 2024

Journal Articles

Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression

Visanu Wanchai, Hongwei Xu, Cody Ashby, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1885.

https://doi.org/10.1182/blood-2024-205344

Published: 2024

Journal Articles

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Criswell L. M. Lavery, Adam Bagg, Mary Jo Lechowicz, Daisy V. Alapat, Amy Chadburn, Megan S Lim, Gordan Srkalovic, Frits van Rhee, Joshua D Brandstadter, David C. Fajgenbaum

Blood (2024) 144 (Supplement 1): 1156.

https://doi.org/10.1182/blood-2024-211190

Published: 2024

Journal Articles

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4729.

https://doi.org/10.1182/blood-2024-193583

Published: 2024

Journal Articles

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Jr, Fenghuang Zhan, Eric Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 3789.

https://doi.org/10.1182/blood-2024-204228

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Sharmilan Thanendrarajan, Phil Farmer, Clyde Bailey, Carolina Schinke, Samer Al Hadidi, Maurizio Zangari, Stephanie Rogers, Anne Williams, Fenghuang Zhan, John D Shaughnessy, Jr, Tanvi H. Patel, Anup Kumar Trikannad, Asis Shrestha, Syed Naqvi, Hira Imad Cheema, Trilok Shrivastava, Manozna Karri, Ramya Bachu, Frits van Rhee

Blood (2024) 144 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2024-206152

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 254.

https://doi.org/10.1182/blood-2024-210725

Published: 2024

Journal Articles

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Rajshekhar Chakraborty, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood (2024) 144 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2024-210478

Published: 2024

Journal Articles

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Nishanth Thalambedu, Jeffery Sawyer, Janet L Lukacs, Phil Farmer, Samer Al-Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Maurizio Zangari

Blood (2024) 144 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2024-211798

Published: 2024

Journal Articles

Identification of Risk Factors for Myeloma Progression in African American Patients

David E. Mery, Yihao Zhan, Hongling Peng, Eric Siegel, Cody Ashby, Clyde Bailey, Catherine Ma, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2024-212173

Published: 2024

Journal Articles

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T Mckay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin H van Vliet, David S. Siegel, Saad Z. Usmani, Frits van Rhee

Blood (2024) 144 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2024-209903

Published: 2024

Journal Articles

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

Catherine Ma, Fumou Sun, Clyde Bailey, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2024-204135

Published: 2024

Journal Articles

Insights into the etiology of Castleman disease

Frits van Rhee, David Fajgenbaum

Blood (2024) 143 (18): 1789–1790.

https://doi.org/10.1182/blood.2023023716

Published: 2024

Journal Articles

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Samer Al Hadidi, Obada Ababneh, Carson W Ercanbrack, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Guido Tricot, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Maurizio Zangari, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2023-181034

Published: 2023

Journal Articles

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Sheila K. Pierson, Joshua D. Brandstadter, Frits van Rhee, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2023-183039

Published: 2023

Journal Articles

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions

Fumou Sun, Yan Cheng, Jin-Ran Chen, Visanu Wanchai, David E. Mery, Hongwei Xu, Dongzheng Gai, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, John D Shaughnessy, Jr, Guido Tricot, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 452.

https://doi.org/10.1182/blood-2023-181853

Published: 2023

Journal Articles

Single Nuclei Multiomics Analysis of Transcriptional and Chromatin Accessibility of Tumor Cells Uncovers Molecular Signatures and Regulatory Elements of Malignant Clonal Evolution in Multiple Myeloma

Visanu Wanchai, Hongwei Xu, Cody Ashby, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 87.

https://doi.org/10.1182/blood-2023-181279

Published: 2023

NARROW

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Identification of Risk Factors for Myeloma Progression in African American Patients

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

Insights into the etiology of Castleman disease

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions

Single Nuclei Multiomics Analysis of Transcriptional and Chromatin Accessibility of Tumor Cells Uncovers Molecular Signatures and Regulatory Elements of Malignant Clonal Evolution in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only